Blog hero background graphic

Blog

The Beghou Biopharma Review

H1’s most consequential commercialization trends; 3 questions for Star Therapeutics’ Jacob Lai

MFN pricing and AI are reshaping biopharma go-to-market strategy. Star Therapeutics' Jacob Lai shares insights on launch sequencing,...

H1’s most consequential commercialization trends; 3 questions for Star Therapeutics’ Jacob Laifeatured image

Why Medical Affairs must be integrated into field strategy

Biopharma’s own AI myth-busters separate tall tale from truism

4 ways leading pharma teams are rethinking IC

Fast 5: MFN has reset pharma launch strategy

Commercializing at FDA Speed in Emerging Biopharma

The Space Life Sciences Podcast

Why capital efficiency anchors biotech’s new commercial playbook

When your data hits a wall: A pragmatic framework for life sciences leaders before investing in more data

Pharma search tipping point: Moving from the solo act of SEO to GEO

The Beghou Biopharma Review

Commercial ops a test bed for moving AI beyond R&D; 3 takes from an HCP- engagement whisperer

Fast 5: Can pharma-AI mega-deals transform commercial ops?

The Space Life Sciences Podcast

Moving clinical minds: Why strong data don't always translate into clinical adoption

Pharma’s vanishing launch window — and what to do about it

Fast 5: From Health AI to Ozempic in kiosks, Amazon further bookends the healthcare journey

Segmenting for Success: A Framework for Driving AI Adoption Across the Commercial Organization

Cell and Gene Therapy in ophthalmology